ABSTRACT

Targeted therapy has gained importance as a consequence of molecular genetics and biological research development. Sorafenib, a multi-tyrosine kinase inhibitor, is one of the options in targeted therapy.

Its effectiveness was proven unresponsive to chemotherapy and radioactive iodine of metastatic well differentiated thyroid carcinoma by Phase II studies. In all the side effects of sorafenib, skin toxicities can be seen at a rate of 25%. Hand-foot syndrome is one of the very important skin toxicities, observed at a rate of 30%, depending upon the diversity and seriousness of the symptoms. For this reason, especially in the absence of alternatives in metastatic thyroid carcinoma treatment, and the approach to the toxic effects of sorafenib, the clinical benefit is considerable with treatment continuance.

In this article, it was aimed to consider the use of sorafenib and three different skin toxicities related with the treatment; its management, situation and treatment approach in a patient having lung metastasis following postoperative and maximum radioactive iodine posttreatment. In addition, the hand-foot syndrome caused by both other tyrosin kinase inhibitors and chemotherapy agents, together with differences and similarities in the management of this case, were emphasised. (Turk J Dermatol 2012; 6: 17-20)